Korro Bio, Inc. (KRRO) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Korro Bio, Inc. (KRRO) closed at USD 8.88 on 2026-10-14, a change of -77.8 % over the past year, with a market capitalization of USD 137.1M.

Korro Bio, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Korro Bio, Inc. key figures

Previous close

USD 8.88 (2026-10-14)

1-year change

-77.8 %

Market cap

USD 137.1M

Enterprise value

USD 64.27M

P/E ratio (trailing)

-0.93

P/E ratio (forward)

-2.11

EPS (trailing)

-9.98

EPS (forward)

-4.42

PEG ratio

n/a

Price to book

1.33

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

8.66

Employees

57

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Korro Bio, Inc.

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Korro Bio, Inc. and compare it with other stocks.